**Research Highlight**

**Concisely convey the main topic(s) of the research**

[***Suggestions: No more than 16 words. Titles are often used in information-retrieval systems. Avoid***

***abbreviations and formulae where possible.***]

**Forename Surname1, Forename Surname1,2, Forename Surname3**

1Department, Institution, City Postcode, Country.

2Department, Institution, City, State Postcode, Country.

3Department, Institution, City Postcode, Province, Country.

**Correspondence to:** Prof./Dr. Forename Surname, Department, Institution, Detailed Address, City Postcode, Country. E-mail: xxxx@xxxx.xxx; ORCID: xxxx

Received: date month year

[e.g.,1 Jan 2021]

**How to Use This Template**

*This template shows the manuscript structure that can be used in a research highlight: Keywords, Main Text, Declarations and References. Please note that each part has a corresponding style, which authors should follow. Please note that the fonts in gray show writing requirements. For any questions, you may contact the* *editorial office**.*

**LEVEL 1 HEADING**

[e.g., MAIN TEXT]

In this section, authors should describe the main text of the manuscript in detail. If necessary, we suggest that authors may set headings (level 1 heading, level 2 heading, level 3 heading, *etc.*) to separate different cases or situations.

**Level 2 heading**

*Level 3 heading*

*Tips:*

*All chemicals used, including generic name(s), dose(s), and route(s) of administration, should be identified precisely.*

**Table 1** (other forms: Tables 1 and 2; Tables 1-3),**Equation (1)** [other forms: Equations (2) and (3); Equations (4-6)] and **Figure 1** (other forms: Figure 1A and B; Figure 2A-C; Figures 1 and 2A; Figures 1, 2A and 3-5) show the examples of diagrams. All the tables, equations and figures should be cited in sequence in the main content near to the first time they appear. For supplementary material, authors may cite table, equation and figure like **Supplementary Table 1**, **Supplementary Equation (1)** and **Supplementary Figure 1**. For details, you may refer to [**Supplementary Material Template**](https://energymaterj.com/files/tpl/energymater/Template_for_Supplementary_Material_energymater.docx).

Tips:

* Results should be presented in a logical sequence;
* Avoid redundant explanations to all the data from the tables or illustrations.

|  |  |
| --- | --- |
| **A** | 图二**B** |
| **C** |

**Figure 1.** We present examples of electron micrograph, non-editable and editable images in Figure 1A-C. A: description of what the Figure 1A is; B: description of what the Figure 1B is; C: description of what the Figure 1C is. This figure is quoted with permission from XX *et al*.[2]

*Figure notes:*

* *Figures should be cited in numeric order (e.g., Figure 1, Figure 2) and placed after the paragraph where it is first cited;*
* *Figures can be submitted in format of tiff, psd, AI or jpeg, with resolution of 300-600 dpi;*
* *Diagrams with describing words (including, flow chart, coordinate diagram, bar chart, line chart, and scatter diagram, etc.) should be editable in word, excel or powerpoint format. Non-English information should be avoided;*
* *Labels, numbers, letters, arrows, and symbols in figure should be clear, of uniform size, and contrast with the background;*
* *Symbols, arrows, numbers, or letters used to identify parts of the illustrations must be identified and explained in the legend;*
* *Internal scale (magnification) should be explained and the staining method in photomicrographs should be identified;*
* *All non-standard abbreviations should be explained in the legend;*
* *Authors should pay attention to the protection of patients’ rights, such as privacy and portrait, and obtain signed patient consent from authors before using any personal information of patients. The patient’s portrait with full characters and his/her real name is not allowed for use;*
* *Permission for use of copyrighted materials from other sources, including re-published, adapted, modified, or partial figures and images from the internet, must be obtained. It is authors’ responsibility to acquire the licenses, to follow any citation instruction requested by third-party rights holders, and cover any supplementary charges.*

|  |  |
| --- | --- |
|  | (1) |

Equation note:

* Equations should be provided in editable form (image file format is not allowed).

**Table 1. This is a table caption. A summary description of this table should be written here**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Authors** | **Regimen** | ***n*** | **Age (year)** | **CR (%)** | **2-year (3-year) EFS/PFS (%)** | **2-year (3-year) OS (%)** |
| Our current study | CHOPCVP | 25167 | 17-8245-87 | 69.829.9\* | 55.3 (46.0)18.0 (12.0)\* | 58.0 (52.0)25.0 (19.0)\* |
| Khaled *et al.*[1] | CHOP | 40 | 19-75 | 67 | 54 (54) | 82 (71) |
| Burton *et al.*[2] | CHOPCIOP | 105106 | 22-6625-67 | 7052 | 4-year PFS: 564-year PFS: 40\* | 4-year OS: 654-year OS: 56# |

This part is footer. \**P* < 0.05, #*P* ≥ 0.05. EFS: event-free survival; PFS: progression-free survival; OS: overall survival; CHOP: cyclophosphamide, doxorubicin, vincristine, and prednisone; CVP: cyclophosphamide, vincristine, and prednisone; CIOP: cyclophosphamide, idarubicin, vincristine, and prednisone; CR: complete response. This table is cited with permission from Li *et al*.[1] published in xxx.

***Table notes:***

* ***Tables should be cited in numeric order and placed after the paragraph where it is first cited;***
* ***The table caption should be placed above the table and labeled sequentially (e.g., Table 1, Table 2);***
* ***Tables should be provided in editable form like DOC or DOCX format (picture is not allowed);***
* ***Abbreviations and symbols used in table should be explained in footnote;***
* ***Explanatory matter should also be placed in footnotes;***
* ***Non-English words should be avoided;***
* ***Permission for use of copyrighted materials from other sources, including re-published, adapted, modified, or partial tables from the internet, must be obtained. It is authors’ responsibility to acquire the licenses, to follow any citation instruction requested by third-party rights holders, and cover any supplementary charges.***

**DECLARATIONS**

**Acknowledgments**

Anyone who contributed towards the article but does not meet [**the criteria**](http://www.icmje.org/recommendations/browse/roles-and-responsibilities/defining-the-role-of-authors-and-contributors.html) for authorship, including those who provided professional writing services or materials, should be acknowledged. Authors should obtain permission to acknowledge from all those mentioned in the Acknowledgments section. This section is not added if the author does not have anyone to acknowledge.

**Authors’ contributions**

Single author:

The author contributed solely to the article.

Two or more authors:

Made substantial contributions to conception and design of the study and performed data analysis and interpretation: Salas H, Castaneda WV;

Performed data acquisition, as well as provided administrative, technical, and material support: Castillo N, Young V

…

**Availability of data and materials**

Authors should declare where the data supporting their findings can be found. Data can be deposited into data repositories or published as supplementary information in the journal. Authors who cannot share their data should state that the data will not be shared and explain it.

If a manuscript does not involve such issue, please state “Not applicable.” in this section.

**Financial support and sponsorship**

If there are sources of funding for the study reported, any relevant grant numbers and the link of funder’s website should be provided if any. The role of the funding body in the experiment design, collection, analysis and interpretation of data, and writing of the manuscript should be declared:

This work was supported by Grant name XX (No. XXXX; No. XXX)...

If there is no grant:

None.

**Conflicts of interest**

If there are any potential conflicts of interest that may be perceived as inappropriately influencing the representation or interpretation of reported research results, please declare here.

If not, please write as “All authors declared that there are no conflicts of interest.”.

Some authors may be bound by confidentiality agreements. In such cases, in place of itemized disclosures, we will require authors to state “All authors declare that they are bound by confidentiality agreements that prevent them from disclosing their conflicts of interest in this work.”.

If authors are unsure whether conflicts of interest exist, please refer to the “Conflicts of Interest” in the [**Editorial Policies**](https://energymaterj.com/pages/view/editorial_policies) of *Energy Materials* for a full explanation.

**Ethical approval and consent to participate**

Not applicable.

**Consent for publication**

Not applicable.

**Copyright**

© The Author(s) 2021.

**REFERENCES**

Authors should cite references **in sequence** throughout the manuscript and indicate them in a superscript square bracket with one citation number[3], two separate citation numbers[4,5] or several consecutive citation numbers[6-9].

* ***We suggest that authors should cite appropriate, traceable and latest references be within recent 5 years;***
* ***Each reference should have a corresponding DOI number/website link;***
* ***Top three authors’ names should be listed in the references;***
* ***The names of journals should be abbreviated according to the style used in Index Medicus (***[***http://www2.bg.am.poznan.pl/czasopisma/medicus.php?lang=eng***](http://www2.bg.am.poznan.pl/czasopisma/medicus.php?lang=eng)***)****.*

Examples of references are shown below:

1. Talukdar S, Bhoopathi P, Emdad L, Das S, Sarkar D, Fisher PB. Dormancy and cancer stem cells: An enigma for cancer therapeutic targeting. *Adv Cancer Res* 2019;141:43-84. [DOI: [10.1016/bs.acr.2018.12.002](https://doi.org/10.1016/bs.acr.2018.12.002)] ***[List all authors when the number of authors is less than or equal to six.]***
2. Jung EM, Clevert DA, Schreyer AG et al. Evaluation of quantitative contrast harmonic imaging to assess malignancy of liver tumors: a prospective controlled two-center study. *World J Gastroenterol* 2007;13:6356-64. [DOI: 10.3748/wjg.v13.i47.6356] ***[List the top three authors when the number of authors is greater than six]***
3. Geraud G, Spierings EL, Keywood C. Tolerability and safety of frovatriptan with short- and long-term use for treatment of migraine and in comparison with sumatriptan. *Headache* 2002;42 Suppl 2:S93-9.
4. Lam SK. Academic investigator’s perspectives of medical treatment for peptic ulcer. In: Swabb EA, Azabo S, editors. Ulcer disease: investigation and basis for therapy. New York: Marcel Dekker; 1991. p. 431-50.
5. Pinotti H, Gama-Rodrigues J, Ellenbogen G, Raia A. Nova técnica no tratamento cirúrgico domegaesôfago. Esofago-cardiomiotomia associada com esofago -fundogastropexia. *Rev Goiana Med* 1974;20:1-13. (in Portuguese)
6. FDA News Release. FDA approval brings first gene therapy to the United States. Available from: <https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm574058.htm>. [Last accessed on 30 Jan 2021]

• See the following website for more types of writing formats:

• <http://www.nlm.nih.gov/bsd/uniform_requirements.html>

***Standard journal articles (list top three authors)***

***Author 1 AB, Author 2 CD, et al. Title of the article. Abbreviated Journal Name Year; Issue: page range. [DOI: xxxxxx]***

***Standard journal articles (organization as author)***

***XXX Research Group. Title of the article. Journal Name Year;Volume:page range. [DOI:xxxx]***

***Standard journal articles (both personal authors and organization as author)***

***Author 1 AB, Author 2 CD; XXX Study Group. Title of the article. Journal Name Year;Volume:page range. [DOI: xxxxxx]***

***Standard journal articles not in English (the title should be translated into English, and clarify the original language in the bracket)***

***Author 1 AB, Author 2 CD. Title of the article. Abbreviated Journal Name Year; Issue: page range. (in Which language)***

***Standard journal articles ahead of print (DOI number should be given)***

***Author 1 AB, Author 2 CD. Title of the article. Abbreviated Journal Name Year; Epub ahead of print [DOI: xxxxxx]***

***Books***

***Author 1 A., Author 2 B. Book Title. 3rd ed. Oxford: Publisher; 2008. pp. 154-196.***

***Chapter in a book***

***Author 1 A., Author 2 B. Book Title. In: Editor 1 C, Editor 2 D, editors. Title of chapter. New York: Publisher; 2002. pp. 93-113.***

***Online resource***

***Title of Site. Title of the article. Available from: URL. [Last accessed on Day Month Year]***

***Conference proceedings***

***Editor 1 AB, Editor 2 CD. Title of Presentation. Proceedings of the Name of the Conference; 2001 Sep 13-15; Leeds, UK. New York: Publisher; 2002.***

***Conference paper***

***Author 1 A., Author 2 B. Title of the article. In: Editor 1 C, Editor 2 D, editors. Name of the Conference 2002: Proceedings of the Name of the Conference; 2002 Apr 3-5; Kinsdale, Ireland. Berlin: Publisher; 2002. pp. 182-91.***

***Unpublished material***

***Author 1 A., Author 2 B. Title of the article. Abbreviated Journal Name Country. Forthcoming Year.***